For example, the use of a selective SETD8 inhibitor (UNC0379) resulted in a significant survival advantage in preclinical xenograft neuroblastoma models, suggesting SETD8 as a candidate therapeutic target in this cancer type [20,21]. This evidence concerns the gene KMT5A and cancer.